Karuna Therapeutics Inc

The KRTX stock trades on Nasdaq All Markets

united states of america therapeutics alzheimers disease mid-cap schizophrenia psychosis psychiatric disorders

Company Description

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions.

Drug Pipeline

Source: Karuna Therapeutics Inc - 20220926

Asset

Indication

Pre-Clinical

Ph1

Ph2

Ph3

Reg/Com

Phase

KarXT

Psychosis

Phase 3

Schizophrenia

Phase 3

Conversation

0 following

0 Comments on KRTX stock

Newest

Trialfinder

beta

RecruitingAn Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With...

RecruitingA Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of...

RecruitingAn Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequate...

Relevant Publications

beta

ACNP 60th Annual Meeting: Poster Abstracts P276 – P550

CPNP 2022 Annual Meeting Poster Abstracts

A Novel Peripheral Biomarker for Depression and Antidepressant Response

Treatment Patterns During Major Depressive Episodes Among Patients with Major Depressive Disorder: A Retrospective Database Analys...

Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizoph...